SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

August 24, 2010 09:01 ET

Radient Pharmaceuticals Announces Availability for Its 2010 Onko-Sure® Reference Guide for Physicians, Oncologists, Clinicians, Consumers & Patients

TUSTIN, CA--(Marketwire - August 24, 2010) -  Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today broad availability of its 2010 Onko-Sure® Reference Guide for the Company's USFDA-approved Onko-Sure® in vitro diagnostic (IVD) cancer test kit.

The 2010 Onko-Sure® Reference Guide is a commercially published compilation of Radient Pharmaceuticals general information and clinical studies on the Company's Onko-Sure® IVD cancer test kit. Designed to provide oncologists, physicians and clinicians with the most current and important information for Onko-Sure®, the guide also serves as a comprehensive reference for other health care professionals, consumers and patients.

In addition to general Company information and Onko-Sure® clinical study data, RPC's 2010 Onko-Sure® Reference Guide provides a comprehensive list of key references, resources and other published materials users can consult to better understand the medical utilities of Onko-Sure®, how healthcare providers and patients can use the test and the science behind Onko-Sure®. 

RPC's Onko-Sure® IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection, screening, and monitoring of various types of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure® is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer detection and monitoring test. 

According to Mr. Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals, "The 2010 Onko-Sure® Reference Guide is an invaluable resource for both members of the healthcare community and patients alike, and we believe it will serve as an important educational tool that will drive broad-based adoption and use of RPC's Onko-Sure® IVD cancer test for the diagnosis, treatment and monitoring of cancer."

RPC's 2010 Onko-Sure® Reference Guide is available in both print and on-line versions. Print versions can be ordered by contacting Radient Pharmaceuticals at 1-714-505-4461 or via e-mail; and online versions are available for download by visiting the Radient Pharmaceuticals corporate website at or RPC's Onko-Sure®-dedicated website located at

RPC Contact Information:
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company's corporate website at For information specifically related to Onko-Sure® visit For Investor Relations information contact Kristine Szarkowitz at or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of our Onko-Sure™ In Vitro Diagnostic cancer test. Our focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve outcomes for patients. Radient Pharmaceutical's current Onko-Sure™ cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Contact Information

  • Radient Pharma Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    Email Contact
    Tel: 206.310.5323